Journal
ULTRASOUND IN MEDICINE AND BIOLOGY
Volume 45, Issue 6, Pages 1455-1465Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ultrasmedbio.2019.01.022
Keywords
Ultrasound molecular imaging; Microbubble; Platelets; Glycoprotein IIb/IIIa; Thrombus
Funding
- Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering
- Fukuda Foundation for Medical Technology
- Japan Agency for Medical Research and Development (AMED) [JP16mk0101037]
Ask authors/readers for more resources
Arginine-glycine-aspartate (RGD)-carrying microbubbles (MBs) have been utilized as a specific contrast agent for glycoprotein IIb/IIIa (alpha(IIb)beta(3) integrin)-expressing activated platelets in ultrasound molecular imaging. Recently, we found that surface modification with lactadherin provides the RGD motif on the surface of phosphatidylserine-containing clinically available MBs, Sonazoid. Here, we examined the potential of lactadherin-bearing Sonazoid MBs to be targeted MBs for glycoprotein IIb/IIIa using the custom-designed in vitro settings with recombinant alpha(IIb)beta(3) integrin, activated platelets or erythrocyte-rich human clots. By modification of the surface with lactadherin, a large number of Sonazoid MBs were attached to the alpha(IIb)beta(3) integrin-coated and platelet-immobilized plate. Additionally, the video intensity of clots after incubation with lactadherin-bearing Sonazoid MBs was significantly higher than that with unmodified Sonazoid MBs, implying the number of attached Sonazoid MBs was increased by the modification with lactadherin. Our results suggest that the lactadherin-bearing Sonazoid MBs have the potential to be thrombus-targeted MBs. (E-mail: otani@ncvc.go.jp) (C) 2019 World Federation for Ultrasound in Medicine & Biology. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available